Multicentre, single-arm, phase II study to evaluate safety and efficacy of cetuximab in combination with oxaliplatin and capecitabine (Xelox) for 12 weeks followed by maintenance treatment with cetuximab plus capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.

Trial Profile

Multicentre, single-arm, phase II study to evaluate safety and efficacy of cetuximab in combination with oxaliplatin and capecitabine (Xelox) for 12 weeks followed by maintenance treatment with cetuximab plus capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2010 Actual patient number (28) added as reported by ClinicalTrials.gov.
    • 24 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top